Descriptive epidemiology of craniopharyngiomas in the United States.
Adamantinomatous
CBTRUS
Craniopharyngiomas
Epidemiology
Papillary
Journal
Pituitary
ISSN: 1573-7403
Titre abrégé: Pituitary
Pays: United States
ID NLM: 9814578
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
accepted:
07
01
2021
pubmed:
29
1
2021
medline:
15
12
2021
entrez:
28
1
2021
Statut:
ppublish
Résumé
Craniopharyngiomas are rare benign brain tumors originating from errors in differentiation during embryogenesis. Given current interest in treatments that target genetic and molecular signatures of specific craniopharyngioma subtypes, updated and comprehensive epidemiologic data of these subtypes are necessary to inform and direct resources. We utilized data from the Central Brain Tumor Registry of the United States (CBTRUS), which represents 100% of the US population. Incidence by demographics was calculated only for histologically-confirmed cases. Age-adjusted annual incidence was calculated and is reported per 100,000 persons. Annual percent change (APC) in incidence rates from 2004 to 2016 was calculated to assess trends. From 2004 to 2016, 7441 craniopharyngiomas were diagnosed in the United States, representing approximately 620 new cases each year. The incidence for histologically-confirmed cases was 0.16 per 100,000 persons. The age distribution was bimodal, with one peak in 5- to 9-year-olds and another in 55- to 69-year-olds. Compared with adamantinomatous tumors, papillary craniopharyngiomas only represented 5.5% of the histologically diagnosed craniopharyngiomas in 0- to 29-year-olds, 30.6% in 30- to 59-year-olds, and 30.4% in 60 + year-olds. Incidence was highest amongst Blacks (0.22), followed by Whites (0.15), Asians or Pacific Islanders (0.14), and American Indians/Alaska Natives (0.10). No significant difference was discovered in incidence rates between males and females or Hispanic and non-Hispanic ethnicities. Craniopharyngiomas are rare tumors with a bimodal age distribution and an equal male-to-female incidence. Black patients had the highest incidence, and adamantinomatous craniopharyngiomas were significantly more common than papillary tumors in adolescent, adult, and elderly populations.
Identifiants
pubmed: 33506438
doi: 10.1007/s11102-021-01127-6
pii: 10.1007/s11102-021-01127-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
517-522Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.
Références
Müller HL, Merchant TE, Warmuth-Metz M et al (2019) Craniopharyngioma. Nat Rev Dis Prim. https://doi.org/10.1038/s41572-019-0125-9
doi: 10.1038/s41572-019-0125-9
pubmed: 31699993
Ostrom QT, Cioffi G, Gittleman H et al (2019) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol 21:v1–v100. https://doi.org/10.1093/neuonc/noz150
doi: 10.1093/neuonc/noz150
pubmed: 31675094
pmcid: 31675094
Cossu G, Jouanneau E, Cavallo LM et al (2020) Surgical management of craniopharyngiomas in adult patients: a systematic review and consensus statement on behalf of the EANS skull base section. Acta Neurochir (Wien) 162:1159–1177. https://doi.org/10.1007/s00701-020-04265-1
doi: 10.1007/s00701-020-04265-1
Bunin GR, Surawicz TS, Witman PA et al (1998) The descriptive epidemiology of craniopharyngioma. J Neurosurg 89:547–551. https://doi.org/10.3171/jns.1998.89.4.0547
doi: 10.3171/jns.1998.89.4.0547
Zacharia BE, Bruce SS, Goldstein H et al (2012) Incidence, treatment and survival of patients with craniopharyngioma in the surveillance, epidemiology and end results program. Neuro Oncol 14:1070–1078. https://doi.org/10.1093/neuonc/nos142
doi: 10.1093/neuonc/nos142
pubmed: 22735773
pmcid: 3408265
Gupta S, Bi WL, Giantini Larsen A et al (2018) Craniopharyngioma: a roadmap for scientific translation. Neurosurg Focus 44:E12. https://doi.org/10.3171/2018.3.FOCUS1861
doi: 10.3171/2018.3.FOCUS1861
pubmed: 29852761
Aylwin SJB, Bodi I, Beaney R (2015) Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor. Pituitary 19:544–546
doi: 10.1007/s11102-015-0663-4
Brastianos PK, Shankar GM, Gill CM et al (2016) Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv310
doi: 10.1093/jnci/djv310
pubmed: 26498373
Sorva R, Heiskanen O (1986) Craniopharyngioma in Finland. A study of 123 cases. Acta Neurochir (Wien) 81:85–89. https://doi.org/10.1007/BF01401226
doi: 10.1007/BF01401226
Weiner HL, Wisoff JH, Rosenberg ME et al (1994) Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery 35:1001. https://doi.org/10.1227/00006123-199412000-00001
doi: 10.1227/00006123-199412000-00001
Crotty TB, Scheithauer BW, Young WFJ et al (1995) Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg 83:206–214. https://doi.org/10.3171/jns.1995.83.2.0206
doi: 10.3171/jns.1995.83.2.0206